

Product Datasheet

PITPNM3 Antibody NBP1-31070

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 4

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-31070

Updated 10/10/2024 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-31070



NBP1-31070**PITPNM3 Antibody**


Product Information	
Unit Size	0.1 ml
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.01% Thimerosal
Isotype	IgG
Purity	Antigen Affinity-purified
Buffer	0.1M Tris (pH 7), 0.1M Glycine, 10% Glycerol
Target Molecular Weight	107 kDa

Product Description	
Host	Rabbit
Gene ID	83394
Gene Symbol	PITPNM3
Species	Human
Immunogen	Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PITPNM3. The exact sequence is proprietary.


Product Application Details	
Applications	Western Blot, Immunocytochemistry/ Immunofluorescence, Knockdown Validated
Recommended Dilutions	Western Blot 1:500-1:3000, Immunocytochemistry/ Immunofluorescence 1:100-1:1000, Knockdown Validated
Application Notes	Knockdown validation (Jiang et al).

Images


Western Blot: PITPNM3 Antibody [NBP1-31070] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with NIR1 antibody [C3], C-term diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.




Immunocytochemistry/Immunofluorescence: PITPNM3 Antibody [NBP1-31070] - Representative fluorescence microscopy images of CCL18 binding to naive CD4+ T cells, knocked down or not for PITPNM3, stained for PITPNM3 and CCL18 3 h after adding CCL18. Scale bar, 5 μ m. Shown are the representative images for three independent experiments using PB T cells from three normal donors. Image collected and cropped by CiteAb from the following publication ([nature.com/articles/cr201734](https://www.nature.com/articles/cr201734)), licensed under a CC-BY license.




Immunocytochemistry/Immunofluorescence: PITPNM3 Antibody [NBP1-31070] - Sample: HeLa cells were fixed in -20C 100% MeOH for 5 min. Green: PITPNM3 protein stained by NIR1 antibody, C-term diluted at 1:500. Blue: Hoechst 33343 staining.



Knockdown Validated: PITPNM3 Antibody [NBP1-31070] - Representative immunoblots showing selective knockdown of PITPNM3 protein in PB CD4+ T cells, but not tumor xenografts (n = 3). Image collected and cropped by CiteAb from the following publication ([nature.com/articles/cr201734](https://www.nature.com/articles/cr201734)), licensed under a CC-BY license.



Knockdown Validated: PITPNM3 Antibody [NBP1-31070] - Immunoblot of CCL18-treated naive CD4+ T cells, knocked down or not for PITPNM3, showing expression of PITPNM3 and phosphorylated/total (t-) Erk1/2 and Akt, relative to GAPDH as a loading control. Blots are representative of data for three donors. Image collected and cropped by CiteAb from the following publication ([nature.com/articles/cr201734](https://www.nature.com/articles/cr201734)), licensed under a CC-BY license.



Publications

Zeng W, Xiong L, Wu W et al. CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype *Oncogene* 2022-11-22 [PMID: 36418470] (FLOW, WB, Human)

Details:

1:1000 WB dilution

Jiang X, Huang Z, Sun X et al. CCL18-NIR1/GPR3 promotes oral cancer cell growth and metastasis by activating the JAK2/STAT3 signalling pathway *BMC Cancer* 2020-07-10 [PMID: 32641093]

Jiang X, Huang Z, Sun X et al. CCL18-NIR1/GPR3 promotes oral cancer cell growth and metastasis by activating the JAK2/STAT3 signalling pathway *assets.researchsquare.com* (WB, ICC/IF, IF/IHC, KD, Human)

Su S, Liao J, Liu J et al. Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer. *Cell Res.* 2017-03-14 [PMID: 28290464] (WB, Human)





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-31070

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

